I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Cancer is a significant cause of mortality in India, and globally as well.\[[@ref1]\] Although other treatment modalities such as radiotherapy, chemotherapy, and surgery have been used, radiotherapy has played an important role in the treatment of cancer.\[[@ref1]\] The capabilities of the principal radiotherapy modality have steadily progressed over the past two decades, i.e., image-based treatment planning with various delivery techniques such as three-dimensional conformal radiation therapy, intensity-modulated radiation therapy (IMRT), and volumetric-modulated arc therapy (VMAT) (RapidArc)\[[@ref2]\] for the treatment of cancers.

IMRT is a sophisticated technique that uses multiple radiation beams to modulate dose intensity and permits the delivery of a highly sculpted dose to the tumor region. This technique helps to deliver the dose to tumor with high conformity as well as sparing of the adjacent organs to a higher level, thereby minimizing toxicities and widening the therapeutic index.\[[@ref3]\]

Otto\[[@ref4]\] proposed VMAT, a new form of intensity-modulated arc therapy optimization where treatment is delivered in a single intensity-modulated arc. With VMAT, three dynamic parameters -- dose rate, beam aperture shape (multileaf collimator), and the speed of gantry rotation can be continuously varied to deliver the prescribed dose to planning target volume (PTV) while sparing the organs at risk (OARs) and healthy tissue.

In external radiotherapy, even though the technologies have improved for conformal delivery of prescribed dose to the tumor, the healthy tissues are unavoidably irradiated. Few studies reported that radiation is one of the clear risk factors for secondary cancers.\[[@ref5][@ref6]\] Risk of secondary malignancy changed based on age, sex, and dose distribution. Risk of secondary malignancy is increased in younger age patients, predominantly among radiation-associated secondary cancers.\[[@ref7][@ref8]\]

Secondary malignancy risk changes (1) according to irradiation of different locations\' healthy tissues and (2) according to different dose distributions such as low, intermediate, and high dose.\[[@ref9][@ref10]\] The different locations of healthy tissues are classified into two categories: (i) healthy tissues within the treatment volume (primary treatment volume) and (ii) the healthy tissues outside of the treatment volume (field edge and peripheral volume).\[[@ref9]\] The different dose distributions are classified into three categories based on the approximate dose level: (i) high dose (\>30 Gy or 50% of the prescribed dose), (ii) intermediate dose (3--30 Gy or 5%--50% of the prescribed dose), and (iii) low dose (\<3 Gy or 5% of the prescribed dose).\[[@ref9]\]

Diallo *et al*. found that 66% of secondary cancers occurred at the periphery of the treatment volume (from the field edge to 5 cm), 22% occurred beyond 5 cm from the treatment field, and 12% occurred within the treatment volume.\[[@ref11]\]

Dose distribution with different delivery techniques differs due to their degrees of freedom. The requirement of each technique is different. For example, method of delivery, required number of monitor units (MUs), number of fields, and treatment time are different.\[[@ref12][@ref13]\] Even if IMRT technique has made it possible to achieve higher dose conformity to the tumor and to reduce the dose to healthy tissue structures, the degree of delivery freedom for dose delivery between IMRT and VMAT are entirely different.\[[@ref14]\] Consequently, the increased degrees of freedom with VMAT technique, whether it helps to reduce dose to healthy tissues without compromising on target coverage and sparing of OARs has to be evaluated.

The quantification of secondary malignancy risk is not trivial due to the missing information on dose distribution.\[[@ref5]\] Therefore, the objective of this study is to categorize the dose in different regions of the irradiated volume for various sites and to evaluate the relationship between the target volume and the dose to healthy tissues. Eventually, the results with VMAT technique are to be compared with the IMRT technique for the evaluation of relative merits.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Source of data {#sec2-1}
--------------

The data were obtained from the Department of Radiation Oncology at Mangalore Institute of Oncology, Mangalore, Karnataka. Informed consent was obtained from the patients or his/her representatives at the beginning of the study after explaining about the treatment technique.

Procedure {#sec2-2}
---------

### Patient positioning, immobilization, and computed tomography simulation {#sec3-1}

A total of 150 patients comprising of 64 (42.70%) head-and-neck cancers, 30 (20.0%) lower third esophagus cancer, 21 (14.0%) cervical cancer with para-aortic nodes involvement, 20 (13.33%) cervical cancer, and 15 (10.00%) prostate cancer were studied. All patients were immobilized with thermoplastic mask and/or Vac-Lok and simulated. Planning computed tomography (CT) images were acquired with a slice thickness of 3 mm.

### Delineation of tumor and critical organs {#sec3-2}

According to the International Commission on Radiation Units and Measurements (ICRU) 62, all tumors and critical structures were delineated on CT. Based on the treatment sites, different margins were given to clinical target volume to account for daily patient setup error during treatment delivery. To find the scatter dose at different regions, three nontargeted healthy tissues were delineated: (a) healthy tissues within the treatment volume, (b) healthy tissues from field edge to 5 cm on both side of the treatment volume, and (c) healthy tissues beyond 5 cm of the field edge on both sides of the treatment volume \[[Figure 1](#F1){ref-type="fig"}\].

![The schematic diagram of the classification of healthy tissues](JMP-44-213-g001){#F1}

### Dose prescription {#sec3-3}

The details of the dose prescription case-wise are as follows:

Head and neck: 70 and 54 Gy simultaneously prescribed in 35 fractions to the PTV~70Gy~ and to PTV~54Gy~, respectivelyLower-third esophagus: 60 and 45 Gy simultaneously prescribed in 30 fractions to the PTV~60Gy~ and to PTV~45Gy~, respectivelyCervix with PA involvement: 54 Gy in 27 fractions to the PTV~54Gy~ and 45 Gy in 25 fractions to the PTV~45Gy~ was prescribedCervix: 54 Gy in 27 fractions was prescribed to the PTV~54Gy~Prostate: 80 Gy and 54 Gy simultaneously prescribed in 40 fractions to the PTV~80Gy~ and to seminal vesicles, respectively.

### Treatment planning {#sec3-4}

For all the patients, two sets of treatment plans, one with IMRT and another with VMAT were generated in Varian Eclipse treatment planning system (10.0.39). According to the Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) and ICRU 62, the planning objectives were defined.

### Volumetric-modulated arc therapy (RapidArc) plan {#sec3-5}

VMAT plans were generated for all the patients with 1--2 RapidArc fields with arc lengths of 656°--716°, and the collimator angle ± 20° was given for all the arc fields. The generated treatment plans were optimized with progressive resolution optimizer-III algorithm to meet the given planning objectives. Dose to tumor and critical structures by the optimized plan was calculated in AAA algorithm with 2.5-mm grid resolution and inhomogeneity correction "ON" for 6 MV energy. The plan was evaluated with the planning objectives. A verification plan of the evaluated plan was calculated and analyzed against the measurement values using portal dosimetry.

### Intensity-modulated radiation therapy plan {#sec3-6}

Similarly, IMRT plan for each patient was generated with 7--9 fields with equal intervals of gantry angle, and the collimator angle of all the fields was ± 20°. The created treatment plans were optimized using dose-volume optimizer to meet the same given planning objectives. Dose to the tumor and critical structures by the optimized plan was calculated in AAA algorithm with 2.5-mm grid resolution and inhomogeneity correction ON for 6 MV energy. The plan was evaluated with the planning objectives in mind. A verification plan of the evaluated plan was calculated and analyzed against the measurement values using portal dosimetry.

Plan evaluation {#sec2-3}
---------------

Confirmation number (CN), ICRU recommended conformity index (CI), coverage index (COVI), homogeneity index (HI), and dose gradient index (GI) were used for the evaluation of tumor dose coverage with both plans. In the evaluation of OARs sparing level, QUANTEC recommendations were followed. While selecting a relatively better plan for treatment, the high dose (50%) receiving percentage of healthy tissue volume within treatment volume as well as the volume from field edge to 5 cm outside the treatment volume receiving low dose (5%) and intermediate dose (10%) were also analyzed with VMAT and IMRT techniques. All the above-mentioned doses and healthy tissue volume of all the treatment sites were noted down in percentage for comparison between VMAT and IMRT as well as to find the relationship between tumor volume and dose to healthy tissue volume.

These values were analyzed and compared between VMAT and IMRT in each site separately. A graph was plotted using all sites\' values to assess the relationship between tumor volumes and percentage of healthy tissue volume at each dose level separately. The required number of MU for VMAT and IMRT plans was also recorded and compared.

The healthy tissue volume beyond 5 cm from the field edges was not reported due to inadequately acquired CT images.

Statistics {#sec2-4}
----------

The descriptive and inferential statistics of between-group comparison of both dosimetric and technical parameters was performed using the IBM SPSS version "16" (IBM, Chicago, IL, USA).

The statistical inferences were made for alpha (α) at 5% (*P* \< 0.05), 80% power (1-β), and 95% of confidence interval. *P* \< 0.05 was considered as statistically significant. Paired *t*-tests and Wilcoxon signed-rank test were used to compare the mean of the plans between the techniques.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

[Table 1](#T1){ref-type="table"} shows the descriptive statistics of the tumor volumes in the various treatment sites. In this, prostate cancer tumor volume was the smallest one and cervix with para-aortic nodes involvement was the largest one. The tumor volume of head-and-neck and esophagus cancers is closer to each other. The tumor volume of cervix cancer is the second largest volume.

###### 

Descriptive statistics of the various treatment site tumor volumes

  Treatment sites, *n* (%)    All targets' volume (cubic centimeter)                   
  --------------------------- ---------------------------------------- ------ -------- --------
  Head and neck - 64 (42.7)   609.29±194.39                            154    1286     598.11
  Esophagus - 30 (20)         820.84±292.18                            385    2007     750.5
  Cervix-PA - 21 (14)         2128.30±695.95                           1272   3405.4   1976
  Cervix - 20 (13.3)          1273.12±340.02                           769    2028     1258.5
  Prostate - 15 (10)          256.75±213.57                            93.1   727      179.22

Cervix-PA: Cervical cancer with para-aortic nodes involvement, SD: Standard deviation

Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} show that both VMAT and IMRT plans achieved acceptable tumor coverage and spared the critical structures below the tolerance. However, VMAT shows significantly better CN and CI along with higher sparing of critical structures in all the treatment sites.

###### 

Site-wise comparison results of various indices for target dose coverage

  Site (*n*)                   Indices      Mean±SD       *P*\*        
  ---------------------------- ------------ ------------- ------------ ---------
  Head and neck (64)           CN           0.822±0.07    0.739±0.09   \<0.001
  DGI                          0.113±0.05   0.110±0.052   0.015        
  COVI                         0.980±0.02   0.977±0.03    0.102        
  CI                           1.184±0.12   1.313±0.18    \<0.001      
  HI                           0.087±0.02   0.096±0.03    0.013        
  Lower-third esophagus (30)   CN           0.899±0.04    0.811±0.07   \<0.001
  DGI                          0.182±0.06   0.150±0.06    \<0.001      
  COVI                         0.960±0.02   0.926±0.05    0.001        
  CI                           1.033±0.03   1.061±0.09    0.078        
  HI                           0.125±0.06   0.106±0.03    0.110        
  Cervix -PA (21)              CN           0.804±0.07    0.713±0.08   \<0.001
  DGI                          0.262±0.05   0.249±0.05    0.024        
  COVI                         0.971±0.03   0.973±0.03    0.571        
  CI                           1.178±0.12   1.346±0.17    \<0.001      
  HI                           0.126±0.03   0.140±0.07    0.374        
  Cervix (20)                  CN           0.819±0.05    0.747±0.07   \<0.001
  DGI                          0.239±0.03   0.219±0.03    \<0.001      
  COVI                         0.980±0.01   0.983±0.01    0.926        
  CI                           1.185±0.08   1.306±0.13    \<0.001      
  HI                           0.096±0.02   0.112±0.04    0.074        
  Prostate (15)                CN           0.876±0.05    0.792±0.08   \<0.001
  DGI                          0.196±0.07   0.161±0.06    \<0.001      
  COVI                         0.970±0.02   0.960±0.05    0.117        
  CI                           1.085±0.08   1.167±0.16    0.013        
  HI                           0.074±0.02   0.099±0.04    0.046        

\*Paired *t*-test. VMAT: Volumetric-modulated arc therapy, IMRT: Intensity-modulated radiation therapy, Cervix-PA: Cervical cancer with para-aortic nodes involvement, CN: Confirmation number, DGI: Dose Gradient Index, COVI: Coverage Index, CI: Conformity Index, HI: Homogeneity Index, SD: Standard deviation

###### 

Site-wise comparison of doses to various organs at risk

  Treatment site       OARs               Planning objectives   Mean±SD        *P*\*          
  -------------------- ------------------ --------------------- -------------- -------------- -------
  Head and neck (64)   Spinal cord        D~max~\<45 Gy         39.685±3.72    40.918±5.10    0.013
  Left parotid         Mean\<26 Gy        21.795±10.40          22.600±10.74   0.012          
  Right parotid        Mean\<26 Gy        20.857±8.97           22.04±8.87     0.001          
  Larynx               Mean\<35 Gy        38.635±7.90           40.758±8.24    0.011          
  Oral cavity          Mean\<45 Gy        33.874±9.19           36.381±8.77    \<0.001        
  Esophagus (30)       Spinal cord        D~max~\<45 Gy         37.52±3.83     39.822±5.10    0.002
  Total lung           Mean\<17 Gy        15.758±2.72           16.461±2.83    0.022          
                       V~20Gy~\<25%       24.127±9.02           29.034±11.80   0.004          
  Heart                Mean\<26 Gy        31.456±5.98           32.382±6.91    0.171          
                       V~30Gy~\<46%       43.682±17.71          48.129±23.71   0.089          
  Liver                Mean\<20 Gy        14.33±6.73            15.058±6.95    0.017          
  Left kidney          Mean\<15 Gy        5.288±3.15            6.167±4.16     0.174          
  Right kidney         Mean\<15 Gy        3.202±2.26            3.447±2.42     0.468          
  Cervix - PA (21)     Bladder            D~2%~\<58.5 Gy        56.617±2.16    59.750±8.91    0.135
  Rectum               D~2%~\<58.5 Gy     55.182±2.02           54.735±3.13    0.346          
  Left-FH              Mean=Minimize      29.766±3.70           30.706±5.64    0.503          
  Right-FH             Mean=Minimize      30.191±3.55           29.327±6.36    0.558          
  Small bowel          D~40%~=Minimize    29.480±3.86           31.812±3.25    0.006          
  D~2%~\<58.5 Gy       48.743±3.88        51.287±3.91           0.027                         
  Spinal cord          D~max~\<45 Gy      35.230±10.96          35.755±7.80    0.660          
  Liver                Mean\<20 Gy        5.371±3.92            5.531±3.92     0.892          
  Left kidney          Mean\<15 Gy        8.125±3.70            9.665±4.30     0.025          
  Right kidney         Mean\<15 Gy        8.561±3.39            9.977±3.81     0.036          
  Bone marrow          Mean=Minimize      31.026±4.68           33.850±6.09    0.002          
                       V~40Gy~=Minimize   32.647±6.01           36.547±7.71    \<0.001        
  Cervix (20)          Bladder            D~2%~\<53.5 Gy        51.845±0.82    52.223±2.16    0.407
  Rectum               D~2%~\<53.5 Gy     49.147±5.00           49.381±3.81    0.616          
  Bone marrow          Mean=Minimize      31.308±2.57           34.884±2.67    \<0.001        
                       V~40gy~=Minimize   18.891±8.56           32.516±14.44   \<0.001        
  Small bowel          D~40%~=Minimize    27.580±5.86           29.830±3.12    0.062          
                       D~2%~\<53.5 Gy     45.418±2.97           45.586±2.81    0.646          
  Left-FH              Mean=Minimize      25.831±4.54           24.356±4.52    0.207          
  Right-FH             Mean=Minimize      26.258±4.40           24.890±5.31    0.129          
  Prostate (15)        Bladder            V~60Gy~\<50%          19.460±11.15   19.258±10.49   0.868
                       V~70Gy~\<35%       13.447±8.39           14.074±9.19    0.420          
                       V~75Gy~\<25%       11.260±7.81           11.737±8.53    0.520          
  Rectum               V~50Gy~\<50%       24.854±9.57           26.311±15.40   0.666          
                       V~60Gy~\<35%       14.763±7.17           15.768±9.52    0.627          
                       V~70Gy~\<20%       8.538±5.04            8.792±5.49     0.830          
  Left-FH              D~2%~\<45 Gy       27.362±3.60           32.157±6.60    0.002          
  Right-FH             D~2%~\<45 Gy       27.922±3.53           32.547±6.65    0.027          

\*Paired *t*-test. VMAT: Volumetric-modulated arc therapy, IMRT: Intensity-modulated radiation therapy, OARs: Organs at risk, D~max~: Maximum dose (Gy), V~xGy~: X~Gy~ dose received volume (%), D~2%~: 2% volume received dose (Gy), FH: Femoral head, SD: Standard deviation

[Table 4](#T4){ref-type="table"} describes the comparison results of low-dose, intermediate-dose, and high-dose received by healthy tissue volume within the treatment volume. Volume of healthy tissue received the low and intermediate-dose was significantly lesser (*P* \< 0.05) in IMRT in the treatment of prostate and lower-third esophagus cancer, whereas in the treatment of head-and-neck cancers, cervix, and cervix with para-aortic nodes involvement, the healthy volume did not differ significantly between VMAT and IMRT. However, the healthy tissue volume with high-dose was significantly lesser (*P* \< 0.05) in VMAT in all the treatment sites, than IMRT.

###### 

Percentage of healthy tissues volume of different doses in the treatment volume in volumetric-modulated arc therapy and intensity-modulated radiation therapy techniques

  Different dose to healthy tissues site wise (%)   Dose received volume of healthy tissues within treatment region, mean±SD   *P*            
  ------------------------------------------------- -------------------------------------------------------------------------- -------------- -------------
  Head and neck                                                                                                                               
   Low dose (5)                                     94.397±4.28                                                                93.757±4.19    0.038\*
   Intermediate dose (10)                           83.316±9.19                                                                85.410±7.69    \<0.001\*
   High dose (50)                                   15.501±12.93                                                               20.241±15.59   \<0.001^\$^
  Esophagus                                                                                                                                   
   Low dose (5)                                     94.457±2.74                                                                92.041±4.10    \<0.001\*
   Intermediate dose (10)                           74.481±10.97                                                               74.264±9.75    0.846\*
   High dose (50)                                   9.469±5.54                                                                 12.831±6.39    \<0.001^\$^
  Cervix-PA                                                                                                                                   
   Low dose (5)                                     97.516±1.80                                                                97.098±6.62    0.780\*
   Intermediate dose (10)                           87.392±7.81                                                                89.727±11.44   0.381\*
   High dose (50)                                   13.351±16.26                                                               22.511±18.10   \<0.001^\$^
  Cervix                                                                                                                                      
   Low dose (5)                                     96.027±4.41                                                                96.994±2.17    0.225\*
   Intermediate dose (10)                           86.764±8.14                                                                87.772±6.02    0.262\*
   High dose (50)                                   19.835±8.89                                                                24.925±11.37   \<0.001^\$^
  Prostate                                                                                                                                    
   Low dose (5)                                     95.661±1.53                                                                92.055±6.13    0.025\*
   Intermediate dose (10)                           82.555±5.22                                                                75.772±9.74    0.008\*
   High dose (50)                                   6.163±3.13                                                                 8.355±3.43     \<0.001^\$^

All the values are in percentage. \*Paired *t*-test, ^\$^Wilcoxon signed-rank test. VMAT: Volumetric-modulated arc therapy, IMRT: Intensity-modulated radiation therapy, Cervix-PA: Cervix with para-aortic nodes involvement, SD: Standard deviation

[Table 5](#T5){ref-type="table"} describes the comparison results of volume of healthy tissue received low and intermediate-dose from field edge to 5 cm. Both volume of healthy tissue received low-dose and volume of healthy tissue received intermediate-dose were significantly lesser (*P* \< 0.05) in VMAT in all the treatment sites than IMRT. The table shows that as the target volume increased, the volume of healthy tissue with low and intermediate-dose also increased.

###### 

Percentage of healthy tissues volume of different doses at the volume of field edge to 5cm in volumetric-modulated arc therapy and intensity-modulated radiation therapy techniques

  Different dose to healthy tissues site wise (%)   Dose received volume of healthy tissues from field edge to 5 cm, smean±SD   *P*^\$^        
  ------------------------------------------------- --------------------------------------------------------------------------- -------------- ---------
  Head and neck                                                                                                                                
   Low dose (5)                                     19.064±11.94                                                                27.342±15.89   \<0.001
   Intermediate dose (10)                           5.817±9.16                                                                  11.204±11.38   \<0.001
  Esophagus                                                                                                                                    
   Low dose (5)                                     12.837±12.16                                                                14.380±11.78   0.001
   Intermediate dose (10)                           3.807±8.37                                                                  4.731±8.93     \<0.001
  Cervix-PA                                                                                                                                    
   Low dose (5)                                     27.708±17.63                                                                37.221±18.67   \<0.001
   Intermediate dose (10)                           8.737±7.57                                                                  14.137±9.45    \<0.001
  Cervix                                                                                                                                       
   Low dose (5)                                     22.417±12.20                                                                28.845±12.40   \<0.001
   Intermediate dose (10)                           5.761±4.80                                                                  9.616±6.80     \<0.001
  Prostate                                                                                                                                     
   Low dose (5)                                     8.965±3.70                                                                  12.081±5.69    0.002
   Intermediate dose (10)                           1.525±0.84                                                                  3.181±1.86     0.001

All the values are in percentage. ^\$^Wilcoxon signed-rank test. VMAT: Volumetric-modulated arc therapy, IMRT: Intensity-modulated radiation therapy, Cervix-PA: Cervix with para-aortic nodes involvement, SD: Standard deviation

The required MU in VMAT technique was significantly lesser than IMRT technique (*P* \< 0.001). Similar results were observed in all the treatment sites. Especially in the case of cervical cancer with para-aortic nodes involvement, the average required MU in VMAT technique was 30% of the average MU of IMRT technique \[[Table 6](#T6){ref-type="table"}\].

###### 

Required monitor units to deliver the prescribed dose by volumetric-modulated arc therapy and intensity-modulated radiation therapy plan

  Treatment site (*n*)   Mean±SD         Mean difference   *P*\*    
  ---------------------- --------------- ----------------- -------- ---------
  Head and neck (64)     512.9±103.7     2193.1±527.9      1680.2   \<0.001
  Esophagus (30)         423.90±72.15    1461.5±392.49     1037.6   \<0.001
  Cervix-PA (21)         720.0±217.6     2872.0±828.2      2152.0   \<0.001
  Cervix (20)            603.85±96.27    2832.45±531.3     2228.6   \<0.001
  Prostate (15)          566.67±108.84   1318.93±388.15    752.2    \<0.001

\*Paired *t*-test. VMAT: Volumetric-modulated arc therapy, IMRT: Intensity-modulated radiation therapy, Cervix-PA: Cervix with para-aortic nodes involvement, SD: Standard deviation

Figure [2a](#F2){ref-type="fig"}--[c](#F2){ref-type="fig"} show the relationship between tumor volume (cm^3^) and volume of healthy tissue received low, intermediate and high-dose (%) within the treatment field in VMAT (red dots) and IMRT plans (blue dots).

![(a-c) Relation between tumor volume (cm^3^) and dose received by healthy tissue volume (%) within treatment volume. VMAT: Volumetric-modulated arc therapy, IMRT: Intensity-modulated radiation therapy, cc: Cubic centimeter](JMP-44-213-g002){#F2}

[Figure 2a](#F2){ref-type="fig"} shows the low dose delivered to the healthy tissue in IMRT plans was relatively lesser in the case of lesser tumor volume. In the case of larger tumor volume, the volume of healthy tissue with low-dose was similar to each other between VMAT and IMRT plans, and this volume slightly increased as the tumor volume increased in both VMAT and IMRT plans.

Similarly, the intermediate-dose delivered to the healthy tissue in IMRT plans was also relatively lesser in the case of lesser tumor volume. In most of the cases, the healthy tissue volume with intermediate-dose increased as the tumor volume increased in VMAT as well as IMRT plans \[[Figure 2b](#F2){ref-type="fig"}\].

In the case of high dose, VMAT plans reduced the healthy tissue volume with high dose better than IMRT in all the ranges of tumor volume. The healthy tissue volume with high-dose increased slightly as the tumor volume increased in VMAT and IMRT plans \[[Figure 2c](#F2){ref-type="fig"}\].

However, the linear regression coefficients (*R^2^*) of both VMAT and IMRT plans in all the cases indicate that no linear relation existed between the tumor volume and low dose, tumor volume and intermediate dose, as well as tumor volume and high dose to healthy tissues within treatment field \[Figure [2a](#F2){ref-type="fig"}--[c](#F2){ref-type="fig"}\].

Figure [3a](#F3){ref-type="fig"} and [b](#F3){ref-type="fig"} show the relation between tumor volume (cm^3^) and dose received by healthy tissue volume (%) out of treatment field in VMAT (red dots) and IMRT plans (blue dots).

![(a and b) Relation between tumor volume (cm^3^) and dose received by the healthy tissue volume (%) from field edge to 5cm. VMAT: Volumetric-modulated arc therapy, IMRT: Intensity-modulated radiation therapy, cc: Cubic centimeter](JMP-44-213-g003){#F3}

[Figure 3a](#F3){ref-type="fig"} shows that the volume of healthy tissue with low-dose (out of the field) was larger in IMRT plans than VMAT plans. The healthy tissue volume with low-dose did not linearly increase as the target volume increased. Moreover, irradiation of larger healthy tissue volume was observed while treating the target volume between 600 cc to 1100 cc in VMAT as well as IMRT plans.

Similarly, the volume of healthy tissue with intermediate-dose (out of treatment volume) also was larger in IMRT plans than VMAT plans. In this case, we also observed that the healthy tissue volume with intermediate-dose did not linearly increase as the target volume increased. Moreover, irradiation of larger healthy tissue volume was observed while treating the target volume between 600 cc to 1200 cc in VMAT as well as IMRT plans \[[Figure 3b](#F3){ref-type="fig"}\].

The linear regression coefficients (*R^2^*) of both VMAT and IMRT plans indicate that no linear relation existed between tumor volume and volume of healthy tissue with low and intermediate-dose (out of treatment volume) \[Figure [3a](#F3){ref-type="fig"} and [b](#F3){ref-type="fig"}\].

[Figure 4](#F4){ref-type="fig"} shows how many MU were required to deliver the prescribed dose to various target volumes in VMAT (red dots) and IMRT plans (blue dots). The required MU of all the VMAT plans was \<1000 but with IMRT most of the plans required \>1000 MU. The linear regression coefficient (*R^2^* = 0.3011) and gradient (0.6461) of IMRT plans were relatively higher than of VMAT plans (*R*^2^ = 0.2289 and gradient = 0.1097). These values indicate that the required MU increases with IMRT plans as tumor volume increases. However, the lesser *R^2^* value ensures that no strong linear relation exists.

![Relation between tumor volume (cm^3^) and required monitor unit with volumetric-modulated arc therapy and intensity-modulated radiation therapy](JMP-44-213-g004){#F4}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

In the management of cancer, radiotherapy plays an important role.\[[@ref1]\] The different techniques developed are used to achieve conformal dose to tumor as well as reduce the dose to critical structures below the tolerance by modulating the beam intensity.\[[@ref2]\] Although these techniques are achieving the planning goal, irradiation of the nontargeted tissues (healthy tissues) is still unavoidable.\[[@ref9]\]

Based on the three-dose classifications that is low dose, intermediate dose, and high dose, the high-dose irradiation of the healthy tissues within treatment volume as well as low and intermediate doses to healthy tissues outside of the field can cause severe risk of secondary malignancy.\[[@ref11]\]

Irradiated healthy tissue volume and dose distributions are two main factors which might increase the risk of secondary cancers. Especially close to the primary cancer treatment field, bone and soft-tissue sarcoma solid cancers are mostly found.\[[@ref11][@ref15]\] However, the evaluation of dose distribution to these healthy tissues by different modulation techniques may address the relative benefit to reduce the risk of secondary malignancy. Many studies have reported that VMAT achieves better coverage and sparing of OARs than IMRT.\[[@ref16][@ref17][@ref18]\] However, the dose to healthy tissues was not evaluated adequately and there is no current guidance to follow in terms of dosimetry and limitation of the planning systems.\[[@ref9]\] Thus, this comparison study evaluated the dose to healthy tissues within the treatment volume and outside of the treatment volume (field edge to 5 cm) between VMAT and IMRT techniques along with tumor coverage and dose to OARs. Both target coverage and OARs sparing in VMAT technique were significantly better than IMRT.

Brenner *et al*.\[[@ref19]\] and Chaturvedi *et al*.\[[@ref20]\] reported that the majority of cancers occurred in intermediate-to-high-dose regions than the low-dose regions (\<1 Gy). The results of healthy tissue volume with high-dose in VMAT and IMRT plans between 450 cc and 1100 cc (head-and-neck cancer patients) was similar to the highest target volume range. It implies that the complexity of the plan would increase the high dose to healthy tissues even with smaller tumor volumes. Moreover, the volume of healthy tissue with high-dose within treatment volume is significantly lesser in VMAT technique in all the treatment sites (irrespective of tumor volumes). Therefore, most of the secondary cancer occur in high-dose\[[@ref11]\] can be reduced with VMAT.

Ron *et al*.\[[@ref21]\] reported that dose delivered far outside the primary field is even lesser, and it has also been associated with the risk of second malignancy. Low radiation outside the treatment volume can cause deleterious effects to the patient.\[[@ref21]\] Especially from field edge to 5 cm, the secondary malignancy risk is relatively higher.\[[@ref11]\] Our study shows that the volume of healthy tissues from field edge to 5 cm (out of the field) receiving low dose (5%) and intermediate dose (10%) were significantly reduced with VMAT technique. The substantial control of low doses as well as intermediate doses to the nontargeted tissues outside of the treatment volume can reduce the risk of secondary malignancy.

Several studies have reported that the measured dose at peripheral location is directly proportional to the number of MU used and shielding of the machine.\[[@ref22][@ref23]\] The number of MU used in dynamic IMRT delivery can increase the leakage and scatter dose around the patient body which can cause potential risk of secondary malignancy.\[[@ref24]\] The significantly lesser MU of VMAT plan in all the treatment sites will produce lesser leakage and scatter dose as compared to IMRT. Therefore, the healthy tissues in the peripheral region (beyond 5 cm) would receive low doses in larger volumes with IMRT than VMAT.

The calculation of the dose volume beyond 5 cm (peripheral region) requires special attention in beam configuration, and at the same time, the dose contribution from head leakage is predominant.\[[@ref9]\] Therefore, accurate dose measurements have to be carried out for a meaningful comparison of healthy tissue doses in the peripheral region.

C[ONCLUSIONS]{.smallcaps} {#sec1-5}
=========================

Improved delivery technologies help to get a better conformal delivery plan. However, to select a better plan from two different kinds of techniques, the dose to healthy tissues within treatment volume and outside of the treatment volume has to be considered along with the proposed indices such as CI, GI, COVI, and HI.

VMAT plan can achieve better dose control outside of the treatment volume and reduce the volume of healthy tissue receives high-dose within treatment volume than IMRT. VMAT is the most appropriate technique for achieving the given planning objectives than IMRT, especially in the treatment of large tumor volume. Special attention has to be given to the out of field dose to reduce the secondary malignancy risk, especially while treating women and children.
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